Immunovant, Inc.
IMVT · FY2026 · Fiscal year ended Mar 31, 2026 · 10-K filed May 2026
Open the dashboardInfographicSummary
FY2026 key figures
| $ | FY2026 | FY2025 | Change |
|---|---|---|---|
| Revenue | $0K | $0K | |
| Operating income | −$533M | −$438M | −21.6% |
| Net income | −$506M | −$414M | −22.2% |
Latest quarter: Q2 FY2027
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 9, 2026
| $ | Q2 FY2027 | Year earlier | Change |
|---|---|---|---|
| Revenue | $0K | $0K | |
| Operating income | −$97.2M | −$126M | +22.8% |
| Net income | −$97.2M | −$126M | +23.2% |
Q2 FY2027 dashboardQ2 FY2027 infographic
Questions
- What was Immunovant's revenue in FY2026?
- $0K in FY2026 (Fiscal year ended Mar 31, 2026), no comparable figure vs $0K a year earlier, per its 10-K filed May 2026.
- Was Immunovant profitable in FY2026?
- No: net income was −$506M and operating income −$533M in FY2026.
- What was Immunovant's revenue in Q2 FY2027?
- $0K (n/a vs a year earlier), per its Form 10-Q filed Nov 9, 2026.